ESM Technologies, the leading supplier of innovative, commercialized eggshell and eggshell membrane wellness ingredients, has received a Notice of Allowance from the U.S. Patent and Trademark Office for their application (US 11/683,268) entitled “Anti-Inflammatory Activity of Eggshell Membrane and Processed Eggshell Membrane Preparations”.
“This allowance will build upon the patent support of our flagship eggshell membrane ingredient and the intellectual property behind processing the unique ingredient and its novel uses,” said Dr. Kevin J. Ruff, director of scientific and regulatory affairs for ESM Technologies.
ESM holds multiple patents relating to eggshell membrane separation technology and uses for the resulting separated membrane. This most recent patent application builds upon ESM’s prior uses for eggshell membrane by expanding coverage for not only eggshell membrane alone, but also hydrolysates and/or isolates of eggshell membrane and combinations thereof for the reduction of pro-inflammatory cytokines. Eggshell membrane has been shown in vitro to reduce the production of pro-inflammatory cytokines such as Tumor Necrosis Factor alpha (TNF-a) by human immune cells when stimulated [J Med Food (2012) 15:360-368].The allowance of this patent application positions eggshell membrane as a natural composition for supporting a healthy inflammatory response.